Carisma FY2022 net loss $61.2M, rev $9.8M; merger closed

Carisma Therapeutics Inc.

Net loss of $61.2M for year ended Dec 31, 2022 (basic EPS $54.65 loss); compared to $40.8M net loss in 2021.
Total revenue of $9.8M from collaboration with Moderna; no revenue in 2021.
Cash, equivalents, marketable securities $52.0M at Dec 31, 2022; plus $105.3M net from merger and pre-closing financing.
Merger with Sesen Bio closed March 7, 2023; combined company renamed Carisma Therapeutics Inc.
Accumulated deficit $158.2M as of Dec 31, 2022; management expects cash runway through end of 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Carisma Therapeutics Inc. reported the year ended December 31, 2022 results: revenue $ 9,834, net income $ (61,226 ), EPS $ (54.65 ).

Period: the year ended December 31, 2022
Revenue: $ 9,834
Net income: $ (61,226 )
EPS: $ (54.65 )
Result: reported results

Exact text from the filing

INC. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) Year Ended December 31, 2022 2021 Collaboration revenues $ 9,834 $ — Operating expenses: Research and development 56,618 34,387 General and administrative 9,378 6,407 Total operating expenses 65,996 40,794 Operating loss (56,162 ) (40,794 )

View on SEC.gov

Browse all earnings releases →

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-041238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.